Insulet
Builds tubeless Omnipod insulin-delivery systems with automated dosing and glucose-sensor integration.
Something off on this page? Send us feedback.
Profile
Develops and sells tubeless Omnipod insulin-delivery systems, led by Omnipod 5, plus data analytics and a small drug-delivery pod business. Most revenue comes from disposable Omnipod products, with sales concentrated in the United States and dependent on reimbursement, medical-device clearances, manufacturing quality, and third-party glucose-monitor integrations.
Develops, manufactures, and sells the Omnipod platform for people with insulin-dependent diabetes. Omnipod 5 pairs a disposable, tubeless wearable Pod with an automated dosing algorithm, compatible continuous glucose monitors, and smartphone or controller software; Omnipod DASH provides preset continuous delivery, while Classic Omnipod is being phased out. Omnipod Discover adds analytics and reporting, and a smaller drug-delivery business makes pods for Amgen's Neulasta Onpro kit.
Generates most revenue from Omnipod products, with the United States remaining its largest market and international sales spanning Europe, Canada, the Middle East, and Australia. Its model combines recurring disposable-Pod demand, pharmacy and distributor access, automated manufacturing, and sensor integrations. Sales depend on medical-device clearances and reimbursement, while product performance relies on manufacturing quality, third-party glucose-monitor agreements, and limited-source components.
Company facts
Categories
Key statistics
Year to date −48.7% · Average volume (30d) 1.6M
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| Aug 6, 2026 | Robert W. Baird | Target | $175 | |||
| Aug 6, 2026 | Bernstein | Reiterate | Outperform | $200 | $175 | |
| Aug 6, 2026 | Leerink Partners | Downgrade | Outperform | Market Perform | $145 | |
| Aug 6, 2026 | RBC Capital | Reiterate | Outperform | $245 | $160 | |
| Aug 6, 2026 | BTIG | Downgrade | Buy | Neutral |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 5, 2026Q2 FY26 | $1.47 | $1.66 | +12.9% | $787.4M | $801.7M | +1.8% | −20.12% |
| May 6, 2026Q1 FY26 | $1.19 | $1.42 | +19.3% | $729.9M | $761.7M | +4.4% | +6.03% |
| Feb 18, 2026Q4 FY25 | $1.47 | $1.55 | +5.4% | $769.0M | $783.8M | +1.9% | −3.48% |
| Nov 6, 2025Q3 FY25 | $1.14 | $1.24 | +8.8% | $678.4M | $706.3M | +4.1% | −1.11% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $569.0M | $649.1M | $706.3M | $783.8M | $761.7M | $801.7M | |
| Gross profit | $409.0M | $452.2M | $510.1M | $568.6M | $529.1M | $562.6M | |
| Operating income | $88.8M | $121.1M | $117.7M | $146.3M | $122.1M | $129.7M | |
| Net income | $35.4M | $22.5M | $87.6M | $101.6M | $91.1M | $95.0M | |
| Diluted EPS | $0.50 | $0.32 | $1.24 | $1.44 | $1.30 | $1.37 | |
| Gross margin | 71.9% | 69.7% | 72.2% | 72.5% | 69.5% | 70.2% | |
| Operating margin | 15.6% | 18.7% | 16.7% | 18.7% | 16.0% | 16.2% |
Fiscal years (4-quarter sums)FY21 $1.10B · FY22 $1.31B · FY23 $1.70B · FY24 $2.07B · FY25 $2.71B
Revenue by product · Q2 FY26
Revenue by geography · Q2 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $534.9M · Total debt $948.4M · Total assets $3.17B · Shareholders' equity $1.42B
Dividends
No dividends on record.
Ownership
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 69.26M · Float 68.96M · 99.6% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 6.69M | 9.66% | 13F | Aug 7, 2026 |
| Vanguard Capital Management LLC | 4.53M | 6.53% | 13F | Aug 13, 2026 |
| State Street Corp | 3.20M | 4.62% | 13F | Aug 7, 2026 |
| Vanguard Portfolio Management LLC | 3.08M | 4.44% | 13F | Aug 13, 2026 |
| AQR Capital Management LLC | 2.46M | 3.54% | 13F | Aug 14, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 21, 2026 | Ashley McEvoy | director, officer: President and CEO | +1,100 | $147.47 |
| Jun 3, 2026 | Luciana Borio | director | −418 | $143.27 |
| Jun 3, 2026 | Timothy C. Stonesifer | director | +2,790 | $143.51 |
| Feb 25, 2026 | Michael R. Minogue | director | +2,030 | $246.23 |
| Feb 20, 2026 | Ashley McEvoy | director, officer: President and CEO | +4,300 | $239.35 |
Peers
- Medtronic
Broad AID and pump rival through MiniMed 780G systems
- Tandem Diabetes Care
Pure-play insulin pump rival across AID, Mobi, and patch roadmap
- Beta Bionics
AID pump rival with iLet and a planned tubeless Mint patch pump
- Modular Medical
Emerging tubeless patch-pump and MDI-conversion overlap
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Insulet | $145.31 | +0.11% | $10.05B | 27.1 | 21.0 | 3.3 | +23.5% |
| Medtronic | $91.58 | +0.42% | $116.78B | 24.5 | 15.3 | 3.2 | +9.9% |
| Tandem Diabetes Care | $21.16 | −1.26% | $1.47B | — | — | 1.4 | +5.8% |
| Beta Bionics | $20.11 | +2.08% | $887.2M | — | — | 7.5 | +37.8% |
| Modular Medical | $3.88 | +13.12% | $7.3M | — | — | — | — |
| Median | 24.5 | 15.3 | 3.2 | +9.9% |